Literature DB >> 8948636

p53 regulates the minimal promoter of the human topoisomerase IIalpha gene.

M I Sandri1, R J Isaacs, W M Ongkeko, A L Harris, I D Hickson, M Broggini, F Vikhanskaya.   

Abstract

DNA topoisomerase IIalpha is an essential enzyme for chromosome segregation during mitosis. Consistent with a cell division-specific role, the expression of the topoisomerase IIalpha gene is strongly influenced by the proliferation status of cells. The p53 protein is one of the most important regulators of cell cycle progression in mammals, with an apparent dual role in the induction of cell cycle arrest following cytotoxic insults and in the regulation of the apoptotic cell death pathway. We have analysed whether p53 plays a role in regulating expression of the human topoisomerase IIalpha gene. We show that wild-type, but not mutant, p53 is able to decrease substantially the activity of the full length topoisomerase IIalpha gene promoter. Using a series of constructs comprising various deleted or mutated versions of the promoter lacking critical cis-acting elements, we show that this p53-specific regulation of the topoisomerase IIalpha promoter is independent of all characterised transcription factor binding sites and is directed at the minimal gene promoter. We conclude that expression of wild-type p53 induces downregulation of the human topoisomerase IIalpha promoter by acting on the basal transcription machinery. These findings implicate topoisomerase II as one of the downstream targets for p53-dependent regulation of cell cycle progression in human cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8948636      PMCID: PMC146283          DOI: 10.1093/nar/24.22.4464

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  61 in total

1.  Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

Authors:  F H Drake; G A Hofmann; H F Bartus; M R Mattern; S T Crooke; C K Mirabelli
Journal:  Biochemistry       Date:  1989-10-03       Impact factor: 3.162

2.  Multiple cooperative interactions constrain BPV-1 E2 dependent activation of transcription.

Authors:  M Sowden; S Harrison; R Ashfield; A J Kingsman; S M Kingsman
Journal:  Nucleic Acids Res       Date:  1989-04-25       Impact factor: 16.971

3.  A subthreshold level of DNA topoisomerases leads to the excision of yeast rDNA as extrachromosomal rings.

Authors:  R A Kim; J C Wang
Journal:  Cell       Date:  1989-06-16       Impact factor: 41.582

4.  Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes.

Authors:  T D Chung; F H Drake; K B Tan; S R Per; S T Crooke; C K Mirabelli
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

5.  DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage.

Authors:  C Holm; T Stearns; D Botstein
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

6.  Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22.

Authors:  M Tsai-Pflugfelder; L F Liu; A A Liu; K M Tewey; J Whang-Peng; T Knutsen; K Huebner; C M Croce; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

7.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

8.  Mitotic recombination in the rDNA of S. cerevisiae is suppressed by the combined action of DNA topoisomerases I and II.

Authors:  M F Christman; F S Dietrich; G R Fink
Journal:  Cell       Date:  1988-11-04       Impact factor: 41.582

9.  Regulation of the human topoisomerase IIalpha gene promoter in confluence-arrested cells.

Authors:  R J Isaacs; A L Harris; I D Hickson
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

10.  Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells.

Authors:  H J Huang; J K Yee; J Y Shew; P L Chen; R Bookstein; T Friedmann; E Y Lee; W H Lee
Journal:  Science       Date:  1988-12-16       Impact factor: 47.728

View more
  15 in total

1.  Repression of CDK1 and other genes with CDE and CHR promoter elements during DNA damage-induced G(2)/M arrest in human cells.

Authors:  C Badie; J E Itzhaki; M J Sullivan; A J Carpenter; A C Porter
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas.

Authors:  Xiao-Ling Xu; Wei-Hui Zheng; Zhi-Xuan Fu; Zhu-Peng Li; Hua-Xia Xie; Xian-Xing Li; Lie-Hao Jiang; Yin Wang; Shuang-Mei Zhu; Wei-Min Mao
Journal:  Med Oncol       Date:  2014-11-29       Impact factor: 3.064

3.  Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53.

Authors:  C Huang; N Kohno; H Inufusa; K Kodama; T Taki; M Miyake
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

Review 4.  The regulation of DNA supercoiling across evolution.

Authors:  Alexandre Duprey; Eduardo A Groisman
Journal:  Protein Sci       Date:  2021-08-23       Impact factor: 6.993

5.  Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy.

Authors:  Radoslav Chekerov; Irina Klaman; Menelaos Zafrakas; Dominique Könsgen; Alexander Mustea; Beate Petschke; Werner Lichtenegger; Jalid Sehouli; Edgar Dahl
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

6.  Nitric oxide-induced cellular stress and p53 activation in chronic inflammation.

Authors:  Lorne J Hofseth; Shin'ichi Saito; S Perwez Hussain; Michael G Espey; Katrina M Miranda; Yuzuru Araki; Chamelli Jhappan; Yuichiro Higashimoto; Peijun He; Steven P Linke; Martha M Quezado; Irit Zurer; Varda Rotter; David A Wink; Ettore Appella; Curtis C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-23       Impact factor: 11.205

7.  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

Authors:  George Fountzilas; Christos Valavanis; Vassiliki Kotoula; Anastasia G Eleftheraki; Konstantine T Kalogeras; Olympia Tzaida; Anna Batistatou; Ralf Kronenwett; Ralph M Wirtz; Mattheos Bobos; Eleni Timotheadou; Nikolaos Soupos; George Pentheroudakis; Helen Gogas; Dimitrios Vlachodimitropoulos; Genovefa Polychronidou; Gerasimos Aravantinos; Angelos Koutras; Christos Christodoulou; Dimitrios Pectasides; Petroula Arapantoni
Journal:  J Transl Med       Date:  2012-01-12       Impact factor: 5.531

8.  HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha.

Authors:  Michal Stros; Eva Polanská; Sona Struncová; Sárka Pospísilová
Journal:  Nucleic Acids Res       Date:  2009-02-17       Impact factor: 16.971

9.  Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.

Authors:  G Ferrandina; M Petrillo; A Carbone; G Zannoni; E Martinelli; M Prisco; S Pignata; E Breda; A Savarese; G Scambia
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640

10.  DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer.

Authors:  G MacGrogan; P Rudolph; I de Mascarel Id; L Mauriac; M Durand; A Avril; J M Dilhuydy; J Robert; S Mathoulin-Pélissier; V Picot; A Floquet; G Sierankowski; J M Coindre
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.